- A new vaccine against Covid-19 could be added to those already on the market.
- A large study reported the Novavax vaccine to be 90% effective.
- Novavax’s vaccine was similarly effective against variants of the virus.
Encouraging news. Novavax’s vaccine against Covid-19 showed high effectiveness in a large trial carried out in Mexico and the United States and it also showed protection against variants of the coronavirus, the vaccine manufacturer cited by the AP news agency announced on Monday.
Novavax’s vaccine was 90% effective overall and preliminary data indicated it was safe, the company said, according to the AP report on Monday morning.
The enormous importance of the Novavax vaccine
Although the demand for Covid-19 vaccines has fallen dramatically in the United States, the need for more doses remains critical in many parts of the world. Novavax’s drug, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developed world.
However, the information agency added, there are still months for those reinforcements to arrive, since the pharmaceutical company expected to request authorization for its vaccine in the United States, Europe and other places by the end of September, and to be able to produce up to 100 million doses per month. then.
Novavax vaccine expected to go to “low- and middle-income countries”
“A lot of our first doses will go to … low- and middle-income countries, and that was the goal from the beginning,” Novavax CEO Stanley Erck told The Associated Press.
While more than half of the inhabitants of the United States have received at least one dose of the Covid-19 vaccine, less than 1% of the world’s population has at least one injection, Our World In Data noted, cited by AP .
Novavax vaccine: two doses
The news agency detailed that nearly 30,000 people aged 18 and over in Mexico and the United States participated in the Novavax study. Two-thirds received two doses of the vaccine three weeks apart, while the remainder received a placebo.
There were 77 cases of Covid-19, 14 in the group of vaccinated people and the rest in volunteers who had received the placebo. None of those vaccinated showed moderate or severe symptoms, compared to 14 in the control group, said AP.
Novavax vaccine is effective against virus variants
Another very remarkable fact that AP mentioned is that the Novavax vaccine had a similar effectiveness against several variants including the one identified for the first time in Great Britain and which is dominant in the United States, as well as in high-risk populations such as the elderly and people with other health problems.
Side effects were mostly mild, such as soreness and pain at the injection site. No unusual blood clots or heart problems were reported, Erck told the aforementioned news agency.
Your vaccine technology
Novavax detailed the results in a press release and planned to publish the data in a medical journal, where it will be reviewed by independent experts. The Maryland-based firm had already published data from smaller trials conducted in Britain and South Africa.
Vaccines against Covid-19 prepare the body to recognize the coronavirus, especially the glycoprotein that covers it, and prepare it to fight it. The Novavax vaccine is made from laboratory-grown copies of this protein. It is a different technology than other widely used vaccines, which include genetic instructions for the body to make its own glycoprotein.
Can be stored in normal refrigerators
Novavax vaccine can be stored in standard refrigerators, simplifying distribution. The company had announced a delay in manufacturing due to supply problems, but now expects to reach the capacity to produce 100 million doses a month by the end of September, and 150 million monthly doses by December.
The company has committed to providing 110 million doses to the United States over the next year and a total of 1.1 billion doses to developing countries.
The post Novavax vaccine is 90% effective, large study reports appeared first on Hispanic World.